Effect of glycated hemoglobin on the recurrence rate of paroxysmal atrial fibrillation in patients with type 2 diabetes mellitus who used different glucose-lowering agents
DOI: https://doi.org/10.29296/25877305-2023-06-14
Issue:
6
Year:
2023
Objective. To evaluate the effects of glycated hemoglobin (HbA1c) levels during different glycemic control regimens on the occurrence of paroxysmal atrial fibrillation (AF) episodes in patients with concurrent type 2 diabetes mellitus (DM) (T2DM).
Subjects and methods. The randomized prospective open-label study involved 73 patients (41 males and 32 females; their mean age was 61.4±10.5 years) with paroxysmal AF and T2DM. According to the prescribed therapy, the patients were divided into groups: Group 1 included 39 patients who received combination therapy with dapagliflozin (at a dose of 10 mg/day) and metformin; Group 2 consisted of 34 patients who took sulfonyl urea agents and metformin. The groups were matched for the main clinical and laboratory parameters.
Results. At a HbA1c level of 6.5–7.0%, the patients had significantly less frequently episodes of AF in both groups compared to those having an HbA1c 7.0–7.5% (30.4% versus 77.8%). After treatment, episodes of AF were significantly less frequently seen in Group 1 than in Group 2 (33.3% versus 58.8%; р
Keywords:
endorinology
cardiology
diabetes mellitus
atrial fibrilation
glycated hemoglobin
dapaglilozin
metformin.
References:
- Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12 (10): 1360–420. DOI: 10.1093/europace/euq350
- Fuster V., Ryden L.E., Cannom D.S. et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 123 (10): e269–367. DOI: 10.1161/CIR.0b013e318214876d
- Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020; 42: 373–498. DOI: 10.1093/eurheartj/ehaa612
- American Diabetes Association. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020; 43 (S1): S111–S134. DOI: 10.2337/dc20-s010
- Дедов Д., Мукаилов Н., Евтюхин И. Качество жизни и прогноз у больных АГ и ИБС с фибрилляцией предсердий. Врач. 2013; 7: 72–4 [Dedov D., Mukailov N., Evtyukhin I. Quality of life and prognosis in patients with arterial hypertension and coronary heart disease with atrial fibrillation. Vrach. 2013; 7: 72–4 (in Russ.)].
- Cosentino F., Aboyans V., Bailey C.J. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020; 41 (2): 255–323. DOI: 10.1093/eurheartj/ehz486
- Wang A., Green J. B., Halperin J.L. Atrial Fibrillation and Diabetes Mellitus JACC Review Topic of the Week. JAAC. 2019; 74 (8): 1107–15. DOI: 10.1016/j.jacc.2019.07.020
- Lu Z.H., Liu N., Bai R. et al. HbA1C levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation. Herz. 2015; Suppl. 2:130–6. DOI: 10.1007/s00059-014-4154-6
- Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 2 типа у взрослых: клинические рекомендации. Сахарный диабет. 2020; 23 (S2): 4–102 [Dedov I.I., Shestakova M.V., Mayorov A.Y. et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020; 23 (2S): 4–102 (in Russ.)]. DOI: 10.14341/DM12507
- Cosentino F., Aboyans V., Bailey C.J. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019; 41 (2): 255–323. DOI: 10.1093/eurheartj/ehz486
- McMurray J.J.V., DeMets D.L., Inzucchi S.E. et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019; 21 (5): 665–75. DOI: 10.1002/ejhf.1432
- Butt J.H., Docherty K.F., Jhund P.S. et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022; 24 (3): 513–25. DOI: 10.1002/ejhf.2381
- Zelniker T.A., Bonaca M.P., Furtado R.H.M. et all. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 2020; 141: 1227–34. DOI: 10.1161/CIRCULATIONAHA.119.044183
- Arnett D.K., Blumenthal R.S., Albert M.A. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: 596–646. DOI: 10.1161/CIR.0000000000000678
- Wenwei Q., Zhang N., Korantzopoulos P. et al. Serum glycated hemoglobin level as a predictor of atrial fibrillation: A systematic review with meta-analysis and meta-regression. PLoS One. 2017; 12 (3): e0170955. DOI: 10.1371/journal.pone.0170955
- Aune D., Feng T., Schlesinger S. et al. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018; 32 (5): 501–11. DOI: 10.1016/j.jdiacomp.2018.02.004
- Zhao H., Liu M., Chen Z. et al. Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes. PLoS One. 2020; 15 (2): e0227262. DOI: 10.1371/journal.pone.0227262
- Chang S.H., Wu L.S., Chiou M.J. et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014; 13: 123. DOI: 10.1186/s12933-014-0123-x
- Chen H.Y., Yang F.Y., Jong G.P. et al. Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients. Eur J Clin Invest. 2017; 47 (5): 388–93. DOI: 10.1111/eci.12754
- Li W.J., Chen X.Q., Xu L.L. et al. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020; 19 (1): 130. DOI: 10.1186/s12933-020-01105-5